BioNTech (BNTX)
(Delayed Data from NSDQ)
$96.95 USD
-2.05 (-2.07%)
Updated May 24, 2024 04:00 PM ET
After-Market: $96.82 -0.13 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNTX 96.95 -2.05(-2.07%)
Will BNTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNTX
Why Earnings Season Could Be Great for BioNTech (BNTX)
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
Other News for BNTX
Moderna Was Among The Best Performing Large-Cap Stocks Last Week (May 20-May 26, 2024): Are They In Your Portfolio?
Buy Rating on BioNTech SE Amidst Undervaluation and Strong Pipeline Prospects
Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More
Biotech Alert: Searches spiking for these stocks today
Critical Insights From BioNTech Analyst Ratings: What You Need To Know